Summary. Alterations in plasma branched-chain amino acids (valine, isoleucine and leucine) and alanine have been described in patients with insulin-dependent diabetes mellitus who have poor metabolic control. To assess the relevance of these abnormalities as indices of metabolic control, we sequentially evaluated plasma amino acids in 14 poorly controlled diabetics (seven Type 1 (insulin-dependent) and seven Type 2 (non-insulin-dependent) patients) until good control was achieved. The sum of branched-chain amino acids in both groups of uncontrolled diabetic patients was significantly increased compared with the values for the same subjects in good metabolic control. No statistically significant differences were present between ketotic and non-ketotic uncontrolled patients. The amelioration of the diabetic state with either insulin treatment or oral hypoglycaemic agents, reduced progressively branched-chain amino acids. The sum of valine, isoleucine and leucine strictly correlated with daily urinary glucose (r = 0.73), but less well with fasting blood glucose (r = 0.43), nonesterified fatty acids (r = 0.46) and glycosylated haemoglobin (r = 0.38). Alanine did not show any statistically significant differences at various stages of diabetic control. Branched-chain amino acids, but not alanine, may be used as indices of short-term diabetic control.
In diabetes mellitus metabolic alterations involve protein as well as carbohydrate and lipid metabolism. In uncontrolled Type 1 diabetes, plasma concentrations of the branched-chain amino acids (valine, isoleucine and leucine -BCAA) are increased [1] [2] [3] , and rapidly return to normal after insulin administration [4] . Reduced levels ofalanine have also been reported, although there are conflicting data on this subject [2] [3] . Branched-chain amino acids and alanine have been used as indices of metabolic control in diabetic patients treated with either intermittent or continuous subcutaneous insulin administration [5] [6] . The usefulness of amino acid determinations in the assessment of the metabolic control in Type 2 diabetes is the aim of the present study.
Patients and Methods

Patients
Two groups of patients were studied. The first group comprised seven patients (five males and two females), aged 15-55 years (median 45 years), affected by Type 1 diabetes for several years (3-22 years, median 7 years). The second group consisted of seven patients (five males and two females), aged 35455 years (median 54 years), suffering from newly diagnosed Type 2 diabetes. In the second group no therapy had been instituted before the beginning of the study. None of the 14 subjects were obese, and ~ill had normal hepatic and renal function tests. On the first analyses all subjects were in poor metabolic control (Table 1 ) and in seven (five Type 1 and two Type 2 diabetic patients) ketone bodies were present in the urine. Their progress was followed either as outpatients (nine cases) or as inpatients (five cases). All of them were on a normocaloric, restricted carbohydrate diet (26-30kcal/kg of ideal body weight; 45% carbohydrate). Insulin treatment was continued in the seven Type 1 patients, while the Type 2 subjects received glibenclamide (5-15 mg/day). Analyses were repeated after 2 days of treatment and after 4-30 days (median 12 days), when a satisfactory control was achieved (fasting blood glucose < 8.8mmol/l; daily urinary glucose < 55 mmol).
Thirteen healthy subjects (ten males and three females, median age 45 years) were also studied as controls.
Methods
Venous blood samples were drawn from an antecubital vein after an overnight fast in both diabetic and control subjects. Neither insulin nor oral hypoglycaemic agents were given before sampling [7] , and plasma free amino acids [8] . The following parameters were evaluated: the sum of valine, isoleucine and leucine (BCAA) and alanine. The amount of urinary glucose in the 24 h period preceding the analyses was also recorded. Statistical analysis between mean values was performed by means of Student's 't' test for paired and unpaired data.
Results
The different indices of metabolic control and plasma amino acid values in our patients are reported in Table 1 . No differences were present between Type 1 and Type 2 patients. In poorly controlled Type 1 and Type 2 subjects, BCAA levels were significantly higher when compared with control subjects and with values obtained from the same patients when a satisfactory control was achieved. No differences in plasma BCAA were observed between ketonuric (756 + 94 Izmol/1) and non-ketonuric uncontrolled diabetics (630 _+ 40lxmol/l; mean _+ SEM). In both Type 1 and Type 2 patients, the control of diabetes resulted in a progressive decline of BCAA levels, which were reduced to normal when a satisfactory control was achieved. In contrast to BCAA levels, alanine did not show any remarkable variation in the different groups studied. In poorly controlled patients also, the presence of ketone bodies failed to alter fasting alanine levels significantly (ketonuric 323 + 46; non-ketonuric 410 + 55 ~tmol/1, mean + SEM).
In Type 2 patients no differences in insulin were demonstrated during the different stages of the metabolic control (poor control 17 + 3, improved control 18 _ 2; good control 20 ___ 2mU/1, mean + SEM). By contrast glucagon levels, which were high in patients at the first analyses (46.4 + 5.7 pmol/1), progressively fell (improved control 40.7 _ 4.3; good control 34.5 + 3.1 pmol/l, mean ___ SEM; p < 0.05 compared with the corresponding values of uncontrolled diabetic patients).
In the whole group of diabetic patients, a highly significant correlation was demonstrated between fasting BCAA and daily urinary glucose levels (r = 0.73; p < 0.001). Less significant correlations were found between BCAA and blood glucose or nonesterified fatty acid levels (r = 0.43 and r = 0.46 respectively; p < 0.01), and between BCAA and glycosylated haemoglobin (r = 0.38; p < 0.05). By contrast alanine did not correlate with anyofthe different metabolic indices considered.
Discussion
In contrast to most amino acids,. BCAA are mainly oxidized in muscle and not in the liver [9] [10] [11] [12] , and their muscular uptake is under insulin control. Insulin deficiency is probably responsible for increased BCAA levels in Type 1 diabetes, while in Type 2 diabetics insuiin resistance [13] or inappropriately low serum insulin levels may produce the same effect.
Glucagon levels are high in uncontrolled Type 2 patients, but a role of glucagon in metabolic alterations has been shown only with absolute insulin deficiency [14] . Therefore, in our Type 2 patients, hyperglucagonaemia can scarcely be responsible for the observed alterations in amino acid levels.
Our study demonstrated that BCAA levels are markers of short-term metabolic control in diabetes because of the close association with daily urinary glucose. This applies equally to both Type 1 and Type 2 diabetic patients.
In contrast, in our experience alanine does not seem to represent a marker of diabetic control, and this is in agreement with a recent study [3] . A non-significant reduction in alanine (approximately 20%) was present only in ketotic diabetics compared with uncontrolled non-ketotic patients, possibly because of the ability of ketone bodies to decrease substrate availability for gluconeogenesis in both normal [15] and diabetic subjects [16] .
From the present data we conclude that only branched-chain amino acids and not alanine can demonstrate the normalization of intermediate protein metabolism following the achievement of a satisfactory glycaemic profile. In clinical practice, however, we are not able to say if their use, in the assessment of the overall diabetic control, is of some advantage in comparison with traditional indices; moreover their use is limited by the complex procedure for their determination.
